Ardelyx Inc. To Report Third Quarter 2014 Financial Results On November 6, 2014
FREMONT, Calif., Oct. 30, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it will report third quarter 2014 financial results on Thursday, November 6, 2014. Following the announcement, the Ardelyx management team will host a live conference call and webcast at 4:30pm ET to review the Company's financial results and provide a business update.
The live webcast can be accessed by visiting the investor section of Ardelyx's website at ir.ardelyx.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-855-296-9612 (US) or 920-663-6277 (International) to listen to the conference call. The conference ID number for the live call will be 20728157. Following the webcast, an archived version of the call will be available until November 20, 2014.
Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The Company has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor. Ardelyx formed a collaborative partnership with AstraZeneca in October 2012 to develop and commercialize tenapanor. In October 2014, the Company announced positive results from its tenapanor Phase 2b clinical trial in patients with constipation-predominant irritable bowel syndrome. Tenapanor is also being evaluated in ongoing Phase 2 clinical trials in two different indications including ESRD patients on hemodialysis to treat hyperphosphatemia, and stage 3 CKD patients with type 2 diabetes mellitus to treat sodium and fluid overload. In addition to tenapanor, the Company has discovered small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in ESRD, a program licensed to Sanofi, and independently is advancing several additional research programs focused in cardio-renal, gastrointestinal and metabolic diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx's website at www.ardelyx.com.
SOURCE Ardelyx, Inc.